Dashboard
Manage Tickers

EYPT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

eyepoint-pharmaceuticals-may-offer--sell-up-to-200m-common-stock-offering-with-cantor-fitzgerald
Eyepoint Pharmaceuticals May Offer & Sell ...
11/06/2025 23:25:09

- SEC Filing

rbc-capital-maintains-outperform-on-eyepoint-pharmaceuticals-raises-price-target-to-39
RBC Capital Maintains Outperform on EyePoi...
11/06/2025 15:54:17

RBC Capital analyst Lisa Walter maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform and raises the price targ...

eyepoint-pharmaceuticals-q3-eps-085-misses-079-estimate-sales-966000k-miss-3329m-estimate
EyePoint Pharmaceuticals Q3 EPS $(0.85) Mi...
11/05/2025 12:01:08

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estima...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/15/2025 17:07:00

eyepoint-pharmaceuticals-raises-capital-as-it-advances-lead-product-to-pivotal-study
EyePoint Pharmaceuticals Raises Capital As...
10/15/2025 15:01:34

EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding.

reported-earlier-eyepoint-prices-11m-shares-at-12-each-plus-15m-pre-funded-warrants-to-support-clinical-pipeline-expansion
Reported Earlier, EyePoint Prices 11M Shar...
10/15/2025 06:43:27

eyepoint-pharmaceuticals-announces-150m-proposed-public-offering-of-common-stock
EyePoint Pharmaceuticals Announces $150M P...
10/14/2025 20:37:23

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to develo...

eyepoint-pharmaceuticals-initiates-pivotal-phase-3-program-for-duravyu-to-treat-diabetic-macular-edema-expects-first-patient-dosage-in-q1-2026
EyePoint Pharmaceuticals Initiates Pivotal...
10/14/2025 20:03:26

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to develo...

chardan-capital-maintains-buy-on-eyepoint-pharmaceuticals-maintains-27-price-target
Chardan Capital Maintains Buy on EyePoint ...
08/07/2025 12:52:19

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $27 price ...

hc-wainwright--co-maintains-buy-on-eyepoint-pharmaceuticals-raises-price-target-to-23
HC Wainwright & Co. Maintains Buy on EyePo...
08/06/2025 16:38:07

HC Wainwright & Co. analyst Yi Chen maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and raises the price tar...

eyepoint-pharmaceuticals-q2-eps-085-misses-081-estimate-sales-5333m-miss-6627m-estimate
EyePoint Pharmaceuticals Q2 EPS $(0.85) Mi...
08/06/2025 11:03:20

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estima...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

eyepoint-completes-enrollment-for-second-phase-3-amd-trial-eyes-2026-data-for-duravyu
EyePoint Completes Enrollment For Second P...
07/29/2025 11:05:33

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to ...

forecasting-the-future-4-analyst-projections-for-eyepoint-pharmaceuticals
Forecasting The Future: 4 Analyst Projecti...
06/17/2025 18:00:42

rbc-capital-initiates-coverage-on-eyepoint-pharmaceuticals-with-outperform-rating-announces-price-target-of-28
RBC Capital Initiates Coverage On EyePoint...
06/17/2025 14:55:23

RBC Capital analyst Lisa Walter initiates coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Outperform rating and an...

analyst-expectations-for-eyepoint-pharmaceuticalss-future
Analyst Expectations For EyePoint Pharmace...
05/29/2025 19:00:31

hc-wainwright--co-reiterates-buy-on-eyepoint-pharmaceuticals-maintains-22-price-target
HC Wainwright & Co. Reiterates Buy on EyeP...
05/29/2025 16:13:29

HC Wainwright & Co. analyst Yi Chen reiterates EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $22 price...

heico-monro-abercrombie--fitch-joby-aviation-and-other-big-stocks-moving-higher-on-wednesday
Heico, Monro, Abercrombie & Fitch, Joby Av...
05/28/2025 14:23:37

eyepoint-pharma-enrolls-and-randomizes-over-400-patients-in-phase-3-lugano-pivotal-trial-of-duravyu-for-wet-amd-treatment
EyePoint Pharma Enrolls And Randomizes Ove...
05/27/2025 11:02:40

– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest ––  LUCI...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION